公募基金方面，本期较上一期持股增加的公募基金共计21个，主要包括富国医药创新股票A、汇添富创 新医药混合A、工银前沿医疗股票A、汇添富医疗积极成长一年持有混合A、华宝医药生物混合A等，持 股增加占比达0.60%。本期较上一季度持股减少的公募基金共计14个，主要包括汇添富医疗服务灵活配 置混合A、易方达医疗保健行业混合A、富国精准医疗灵活配置混合A、汇添富医药保健混合、工银医 疗保健股票等，持股减少占比达0.75%。本期较上一季度新披露的公募基金共计6个，主要包括惠升医 药健康6个月持有期混合、宝盈优势产业混合A、华泰柏瑞健康生活混合、华宝安元债券A、方正富邦丰 利债券A等。本期较上一季未再披露的公募基金共计240个，主要包括南方中证500ETF、南方医药保健 灵活配置混合A、中欧医疗创新股票A、创新药、中银创新医疗混合A等。 以上内容与数据，与有连云立场无关，不构成投资建议。据此操作，风险自担。 2025年10月29日，海思科(002653.SZ)发布2025年第三季报。截至2025年10月28日，共有42个机构投资 者披露持有海思科A股股份，合计持股量达1.22亿股，占海思科总股本的10.92%。其中，前十 ...

Core Viewpoint - The report highlights the strong performance of the Huatai-PineBridge Medical Active Growth One-Year Holding Mixed A Fund, with a net profit of 510 million yuan in the first half of 2025 and a net asset value growth rate of 35.06% [2]. Fund Performance - As of September 2, the fund's unit net value was 0.847 yuan, with a one-year cumulative net value growth rate of 79.72%, the highest among its peers [2][5]. - The fund's performance over the last three months showed a growth rate of 31.99%, ranking 32 out of 138 comparable funds [5]. - The fund's three-year Sharpe ratio was -0.1852, ranking 85 out of 105 comparable funds [24]. Investment Focus - The fund manager expressed optimism about opportunities in the medical device and innovative drug sectors, emphasizing the importance of self-sufficiency in investments [2]. - The report noted that domestic medical device companies are closing the technological gap with international counterparts, supported by policies encouraging domestic replacements [2]. Valuation Metrics - As of June 30, 2025, the fund's weighted average price-to-earnings (P/E) ratio was approximately 118.27, slightly below the industry average of 120.96 [10]. - The weighted average price-to-book (P/B) ratio was about 5.93, compared to the industry average of 4.07 [10]. - The weighted average price-to-sales (P/S) ratio was around 10.01, while the industry average was 6.52 [10]. Growth Metrics - For the first half of 2025, the weighted revenue growth rate of the fund's stock holdings was 0.17%, while the weighted net profit growth rate was -11.96% [17]. - The fund's average stock position over the last three years was 75.13%, lower than the industry average of 86.95% [29]. Fund Composition - As of June 30, 2025, the fund had a total of 51,000 holders, with individual investors holding 99.64% of the shares [33]. - The top ten holdings included companies such as Sangfor Technologies, Innovent Biologics, and BeiGene [39].

Core Insights - International Medicine (000516.SZ) released its semi-annual report for 2025, indicating that as of August 21, 2025, six institutional investors held a total of 742 million shares, representing 33.14% of the company's total equity [1] - The institutional holding percentage decreased by 0.46 percentage points compared to the previous quarter [1] - Four public funds were disclosed this period, including Huatai-PineBridge Healthcare Active Growth One-Year Holding Mixed A, Golden Eagle Strategy Allocation Mixed, GF Asset Management Prosperity Selection Mixed A, and Zheshang Huijin Transformation Driven [1] - One foreign fund, Hong Kong Central Clearing Limited, reduced its holdings by 0.29% compared to the previous quarter [1]

Group 1 - The core viewpoint of the news is the performance and holdings of the Huatai Fuhua Medical Active Growth One-Year Holding Mixed Fund A, which has shown significant growth in various time frames [1] - As of June 30, 2025, the fund's net value is 0.8287 yuan, with a growth of 1.78% [1] - The fund has achieved a return of 4.71% over the past month, 51.75% over the past six months, and 67.08% year-to-date, ranking 4497 out of 4701, 93 out of 4538, and 117 out of 4492 respectively [1] Group 2 - The top ten stock holdings of the fund account for a total of 61.79%, with significant positions in companies such as Sanofi (10.07%), Innovent Biologics (8.94%), and Kelun-Biotech (8.71%) [1] - The fund was established on August 21, 2020, and has a total scale of 1.922 billion yuan as of June 30, 2025 [1] - The fund manager is Zheng Lei, who has extensive experience in the medical and healthcare investment sector [2]

Group 1 - The core viewpoint of the news is the performance and holdings of the Huatai Fuhua Medical Active Growth One-Year Holding Mixed Fund A, which has shown significant returns in various time frames [1] - As of June 30, 2025, the fund's total assets amount to 1.922 billion yuan, with a recent net value of 0.8263 yuan, reflecting a growth of 1.04% [1] - The fund has achieved a return of 15.15% over the past month, 63.14% over the past six months, and 66.59% year-to-date, ranking 506 out of 4688, 60 out of 4532, and 84 out of 4490 respectively in its category [1] Group 2 - The top ten stock holdings of the fund account for a total of 61.79%, with significant positions in companies such as Sanofi (10.07%), Innovent Biologics (8.94%), and Kelun-Biotech (8.71%) [1] - The fund was established on August 21, 2020, and is managed by Zheng Lei, who has extensive experience in the medical and healthcare investment sector [2]

Group 1 - The core viewpoint of the article highlights the performance of the Huatai-PineBridge Medical Active Growth One-Year Holding Mixed Fund A, which has a latest net value of 0.7909 yuan, reflecting a decline of 1.25% [1] - The fund has shown a one-month return of 14.91%, ranking 312 out of 4699 in its category; a six-month return of 60.28%, ranking 58 out of 4543; and a year-to-date return of 61.47%, ranking 78 out of 4501 [1] - The fund's top ten stock holdings account for a total of 61.79%, with significant positions in companies such as Sangfor Technologies (10.07%), Innovent Biologics (8.94%), and Kelun Pharmaceutical (8.71%) [1] Group 2 - The Huatai-PineBridge Medical Active Growth One-Year Holding Mixed Fund A was established on August 21, 2020, and as of June 30, 2025, it has a total scale of 1.922 billion yuan [1] - The fund manager, Zheng Lei, has a background in social medicine and health management from Fudan University and has held various positions in the finance and investment sectors, including roles at Guotai Junan Securities and China Oceanwide Fund Management [2]

Group 1 - The core viewpoint of the news is the performance and holdings of the Huatai-PineBridge Medical Active Growth One-Year Holding Mixed Fund A, which has shown significant growth in various time frames [1] - As of June 30, 2025, the fund's latest net value is 0.8101 yuan, reflecting a growth of 4.14% [1] - The fund has achieved a one-month return of 21.65%, a six-month return of 64.72%, and a year-to-date return of 63.33%, with respective rankings of 296 out of 4764, 63 out of 4579, and 72 out of 4542 in its category [1] Group 2 - The top ten stock holdings of the fund account for a total of 61.79%, with significant positions in companies such as Sanofi (10.07%), Innovent Biologics (8.94%), and Kelun-Biotech (8.71%) [1] - The fund was established on August 21, 2020, and as of June 30, 2025, it has a total scale of 1.922 billion yuan [1] - The fund manager is Zheng Lei, who has extensive experience in the medical and healthcare investment sector [2]

Core Viewpoint - The AI Fund Huatai Medical Active Growth One-Year Holding Mixed A (009664) reported a profit of 285 million yuan in the second quarter of 2025, with a weighted average profit per fund share of 0.0982 yuan, and a net value growth rate of 17.18% during the reporting period [2]. Fund Performance - As of July 18, the fund's unit net value was 0.799 yuan, with a one-year cumulative net value growth rate of 66.18%, the highest among its peers [2]. - The fund's performance over different time frames includes a three-month growth rate of 38.36% (31/138 among comparable funds), a six-month growth rate of 63.09% (29/138), and a three-year growth rate of -8.32% (65/107) [3]. Fund Management Strategy - The fund manager indicated adjustments in the portfolio during the second quarter, focusing on three main areas: technological innovation, self-sufficiency, and consumer recovery. The manager remains optimistic about industry opportunities driven by new technologies and has increased investments in innovative drugs [2]. - The manager also sees a favorable opportunity for domestic substitution in the medical device sector, particularly for leading companies in critical areas [2]. Fund Composition - As of June 30, the fund's average stock position over the past three years was 75.13%, lower than the industry average of 86.95% [13]. - The fund's top ten holdings include companies such as Sanofi, Innovent Biologics, and BeiGene, indicating a strong focus on the pharmaceutical and biotechnology sectors [17]. Fund Size and Metrics - The fund's size as of the end of the second quarter of 2025 was 1.922 billion yuan [14]. - The fund's maximum drawdown over the past three years was 47.16%, ranking 15th among comparable funds [10].

Group 1 - The core viewpoint of the news is the performance and holdings of the Huatai-PineBridge Medical Active Growth One-Year Holding Mixed Fund A, which has shown significant growth in recent months and year-to-date [1]. - As of June 23, 2025, the fund's latest net value is 0.6735 yuan, reflecting a growth of 2.14% [1]. - The fund's performance over the past month has yielded a return of 9.25%, ranking 105 out of 4699 in its category [1]. - Over the last six months, the fund has achieved a return of 34.70%, ranking 72 out of 4539 [1]. - Year-to-date, the fund has returned 35.79%, ranking 89 out of 4559 [1]. Group 2 - The top ten stock holdings of the fund account for a total of 56.30%, with the largest positions being: Kelun-Botai (9.63%), BeiGene-U (8.84%), and Kangfang Biotech (7.07%) [1]. - The fund was established on August 21, 2020, and as of March 31, 2025, it has a total scale of 1.68 billion yuan [1]. - The fund manager is Zheng Lei, who has extensive experience in the medical and healthcare investment sector [2].

Group 1 - The core viewpoint of the news is the performance and holdings of the Huatai-PineBridge Medical Active Growth One-Year Holding Mixed Fund A, which has shown significant returns in various time frames [1] - As of June 18, 2025, the fund's latest net value is 0.6747 yuan, reflecting a growth of 0.63% [1] - The fund's performance over the past month has yielded a return of 16.12%, ranking 61 out of 4668 in its category [1] - Over the past six months, the fund has achieved a return of 31.70%, ranking 103 out of 4512 [1] - Year-to-date, the fund has returned 35.18%, ranking 89 out of 4534 [1] Group 2 - The top ten stock holdings of the fund account for a total of 56.30%, with the largest holding being Kelun-Botai at 9.63% [1] - Other significant holdings include BeiGene-U (8.84%), Kangfang Biotech (7.07%), and Betta Pharmaceuticals (5.98%) [1] - The fund was established on August 21, 2020, and as of March 31, 2025, it has a total scale of 1.68 billion yuan [1] Group 3 - The fund manager, Zheng Lei, has a background in social medicine and health management from Fudan University and has held various positions in the finance and investment sectors [2] - Zheng Lei has been with Huatai-PineBridge since November 2017 and has managed multiple funds, including the Huatai-PineBridge Medical Active Growth One-Year Holding Mixed Fund since its inception [2]